Table 1 Baseline patient characteristics (KRAS WT).

From: Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

Patient characteristics

Study 2A

Study 2B

CT(No = 25)N (%)

CT + Cet(No = 23)N(%)

CT + Bev(No = 31)N (%)

CT + Bev + Cet(No = 25)N(%)

Median age, years (range)

63 (44–82)

65 (35–82)

64 (45–81)

65 (33–79)

Gender

  Male

16 (64.0)

16 (69.6)

20 (64.5)

16 (64.0)

  Female

9 (36.0)

7 (30.4)

11 (35.5)

9 (36.0)

Performance Status (ECOG)

  0

20 (80.0)

16 (69.6)

25 (83.3)

17 (68.0)

  1–2

5 (20.0)

7 (30.4)

5 (16.7)

8 (32.0)

Tumor localization

  Rectum

8 (32.0)

3 (13.0)

10 (32.3)

4 (16.0)

  Colon

17 (68.0)

20 (87.0)

21 (67.7)

21 (84.0)

Stage at diagnosis

  I-III

6 (24.0)

3 (13.6)

7 (23.3)

6 (25.0)

  IV

19 (76.0)

19 (86.4)

23 (76.7)

18 (75.0)

CT regimen

  FOLFOX

9 (36.0)

9 (39.1)

15 (48.4)

10 (40.0)

  FOLFIRI

16 (64.0)

14 (60.9)

16 (51.6)

15 (60.0)

  1. CT, chemotherapy; Bev, bevacizumab; Cet, cetuximab.
Back to article page